Questions from the public: March 2021 board meeting

## What are the timelines for the publication of the integrated guidance prototype for type 2 diabetes?

## Will there be a consultation on the type 2 diabetes NICE Connect guideline?

Consultation on the draft updated recommendations for medicines in type 2 diabetes will open on 11 August, with publication planned for January 2022. The consultation will provide stakeholders an opportunity to comment on our initial approach to adding additional context to guideline recommendations.

A wider piece of work is looking at integrating all of the NICE type 2 diabetes recommendations. User testing is embedded throughout the development of these prototypes. There will be an alpha available for stakeholders to use and interact with.

## Do you have any updates on the guideline for depression in adults? Can you explain the reason for the delay to its publication?

Further work has been required to work through a series of concerns raised by stakeholders. The draft guideline is planned for consultation from 23 November 2021 to 7 January 2022, and the current anticipated publication date is May 2022.

## Is it possible to say when the draft of the Innovative Medicines Fund (IMF) engagement document is likely to be published? Is there a timeframe for the IMF to go live?

The IMF engagement document is being developed jointly with NHS England and NHS Improvement. As part of the ongoing development stage, we have held multiple listening events with industry bodies, and patient groups representing a wide range of disease areas (including rare diseases) where we have received input from stakeholders to inform the development of the engagement document. The timeline for the release of the engagement document will be announced ahead of the consultation period.

## Could we get an update on what proportion of appraisals are triggering the BIT threshold of £20m in any of the first three years. Approx. a year ago a figure of 34% was given – wondering how that has changed?

The figure for 2020/21 was approximately 30%.

## Are NICE looking at diabetes, depression and obesity guidelines because these areas are highlighted as being of key importance to the NHS post COVID?

Yes these are all areas where NICE has a range of guidance, some of which are currently being updated. Changes to the guidelines programme will ensure that topics are prioritised where this greatest need from the health and care system, and there is new evidence.